Berzosertib --- New Precision Medicine
Hi friends, just adding this topic here - as not sure where it should be posted:
New class of precision medicine strips cancer of its DNA defenses
Date: June 22, 2020
Source: Institute of Cancer Research
A new precision medicine targeting cancer's ability to repair its DNA has shown promising results in the first clinical trial of the drug class.
The new study, designed to test the drug's safety, found that half of patients given the new drug either alone or with platinum chemotherapy saw their cancer stop growing, and two patients saw their tumours shrink or disappear completely.
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
Last Updated: 7/31/2020
ORIGINAL REPORTS | Clinical Trials
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Thank you Kim!
Thank you Kim!
Hi Daniel, "it was my pleasure!" 🤗
Hope that other friends could notice & continue to follow up the progress of this new precision medicine.
Hopefully, there would be more effective weapons to fight against cancer!
Hi friends, just adding the following to this topic:
Addition of ATR Inhibitor Berzosertib to Gemcitabine Improves Progression-Free Survival in Recurrent Platinum-Resistant High-Grade Serous Ovarian Cancer
September 10, 2020
As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, Dana-Farber Cancer Institute, and colleagues, a U.S. Experimental Therapeutics Clinical Trials Network phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia telangiectasia and Rad3-related) kinase inhibitor berzosertib to gemcitabine in women with recurrent platinum-resistant high-grade serous ovarian cancer.
The benefit of the combination was greatest in patients with a platinum-free interval of 3 months or less.
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
15 Jun 2020
To our knowledge, this is the first randomised study of an ATR inhibitor in any tumour type.
This study shows a benefit of adding berzosertib to gemcitabine in platinum-resistant high-grade serous ovarian cancer.
This combination warrants further investigation in this setting.
An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity.
Upon administration, berzosertib selectively binds to and inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway.
This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis.
ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.